Intertransverse Process Block to Improve Quality of Recovery After Cardiac Surgery With Sternotomy
Launched by CHINESE UNIVERSITY OF HONG KONG · Apr 11, 2025
Trial Information
Current as of August 21, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a technique called the intertransverse process block (ITPB) to see if it can help patients recover better after heart surgery, specifically surgeries that involve opening the chest (sternotomy). The researchers want to find out if ITPB can reduce pain, lower the need for strong pain medications like morphine, and improve overall recovery, including how quickly patients can breathe on their own and leave the hospital. They will compare patients who receive the ITPB with a numbing medication to those who receive a placebo (an inactive treatment) to see if there are significant differences in recovery.
To participate in this trial, you need to be an adult (18 years or older) who is scheduled for certain types of elective heart surgeries, such as coronary artery bypass grafting or valve repair. Unfortunately, if you’re having emergency surgery, have had previous chest surgeries, or have chronic pain or certain health issues, you may not be eligible. If you qualify, you can expect to receive either the ITPB treatment or the placebo and be monitored closely during your recovery. This trial is not yet recruiting participants, but it aims to provide valuable insights into improving recovery for heart surgery patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients aged 18 or older
- • undergoing elective coronary artery bypass graft (CABG), valve repair/replacement, or combined CABG/valve procedure via sternotomy.
- Exclusion Criteria:
- • Emergency surgery
- • redo surgery
- • history of thoracotomy or mastectomy
- • patients with history of chronic pain
- • patients on chronic opioids or sedatives
- • renal failure with estimated glomerular filtration rate \<30ml/min (calculated by Cockcroft-Gault formula)
- • intraoperative use of remifentanil
- • unable to provide informed consent.
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Henry Wong
Principal Investigator
Hospital Authority
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported